Examkin

Question

Difficulty: HardGynecologic Oncology

Molecular pathogenesis and unique histologic features dictate the behavior and origins of various gynecologic malignancies. Match each specific gynecologic neoplasm below to its characteristic molecular derangement, pathognomonic histologic finding, or primary clinical driver.

  • Type I Endometrioid AdenocarcinomaOften preceded by hyperplasia; strongly associated with unopposed estrogen and PTEN gene mutations.
  • Type II Serous Endometrial CarcinomaArises in atrophic tissue backgrounds; typically features complex papillae and is driven by TP53 mutations.
  • Granulosa Cell TumorCharacterized by FOXL2 mutations, Call-Exner bodies, and the production of inhibin.
  • Yolk Sac (Endodermal Sinus) TumorFeatures glomerulus-like perivascular structures (Schiller-Duval bodies) and distinctly elevated alpha-fetoprotein.
  • Clear Cell Ovarian CarcinomaCharacterized histologically by hobnail cells; shares a strong pathogenetic link with pelvic endometriosis.

Answer

Type I Endometrioid Adenocarcinoma pairs with PTEN mutations and hyperplasia. Type II Serous Carcinoma pairs with TP53 mutations and atrophic tissue. Granulosa Cell Tumors pair with FOXL2 mutations and inhibin. Yolk Sac Tumors pair with elevated AFP and Schiller-Duval bodies. Clear Cell Ovarian Carcinomas pair with endometriosis and hobnail cells.
The pairings correctly map the fundamental pathophysiology of core gynecologic malignancies. Type I endometrial cancers are estrogen-dependent, driven by PTEN mutations, and arise from hyperplasia. Conversely, Type II serous endometrial cancers are driven by TP53 mutations and arise from atrophic endometrium. In the ovary, granulosa cell tumors (sex cord-stromal) exhibit FOXL2 mutations and Call-Exner bodies, whereas yolk sac tumors (germ cell) feature Schiller-Duval bodies and AFP secretion. Finally, clear cell ovarian carcinomas have a well-documented derivation from endometriosis and exhibit characteristic hobnail histology.

Step-by-Step Solution

1
Differentiate the two major types of endometrial carcinoma based on their molecular and clinical precursors.
Type I is estrogen-driven (PTEN, hyperplasia), whereas Type II is estrogen-independent (TP53, atrophy).
Recognizing the divergence in endometrial cancer pathogenesis is critical for risk stratification.
2
Identify the distinguishing features of the specified non-epithelial ovarian tumors.
Granulosa cell tumors secrete inhibin and have FOXL2 mutations, while Yolk Sac tumors secrete AFP and show Schiller-Duval bodies.
Germ cell and sex cord-stromal tumors have highly specific molecular markers that confirm the diagnosis.
3
Correlate the epithelial ovarian cancer subtype with its distinct clinical association.
Clear cell carcinoma is uniquely linked to a history of endometriosis and presents with hobnail cells.
Endometrioid and clear cell ovarian carcinomas often share a pathogenetic origin in endometriotic implants.

Key Concept

Molecular and histologic classification of gynecologic malignancies.
Rate this question

Topics

Gynecologic Oncology

More questions from this topic